Biotech Business - June 15, 2022
BioLamina opens an office in Boston
BioLamina has announced plans to open an office in the US to further fuel company growth and market expansion. The new office will be in Boston, MA. This strategic move will help BioLamina to better support existing and new customers in the US and brings the company closer geographically to world-renowned science hubs, it states. […]
Biotech Business - May 18, 2022
Immunovia Inc achieves Clinical Laboratory Licensure
The Rhode Island Department of Health has granted Immunovia, Inc., the US subsidiary of Immunovia, Clinical Laboratory licensure. The licensure allows physicians in Rhode Island to order the IMMray PanCan-d test for their patients. “Receiving licensure in Rhode Island now allows us to offer IMMray PanCan-d in 46 states. We expect additional state licensures to […]
Biotech Business - May 13, 2022
Hansa Biopharma announces temporary marketing authorization in Switzerland
Hansa Biopharma has announces that the Swiss Agency for Therapeutic Products (Swissmedic) has granted temporary marketing authorization for Idefirix in adult patients with a positive crossmatch against an available organ from a diseased donor. The use of Idefirix in Switzerland is reserved for patients with a low probability of being transplanted within the framework of […]
New Market - April 4, 2022
Novo Nordisk’s Ozempic 2.0 mg approved in the US
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved a 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for the treatment of adults with type 2 diabetes. Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the […]
New Market - April 1, 2022
InDex Pharmaceuticals prepares for commercialization of cobitolimod
InDex Pharmaceuticals Holding is planning for self-commercialization of the drug candidate cobitolimod in the US with strategic collaborations in other regions. Launch is expected in 2027, with the potential for annual sales to reach more than USD 1 billion, in moderate to severe left-sided ulcerative colitis, states the company. Read more: Hey there Peter Zerhouni, […]
New Market - March 29, 2022
AstraZeneca’s Ondexxya approved in Japan
Ondexxya has been approved in Japan for patients treated with the Factor Xa (FXa) inhibitors apixaban, rivaroxaban or edoxaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ANNEXA-4 Phase III clinical trial showing […]
